NeoGenomics Beats Estimates Driven by Cancer Testing and NGS Growth

In a move reflecting the ongoing expansion in the advanced genetic diagnostics sector, NeoGenomics announced strong Q2 2026 financial results that surpassed analyst estimates for both earnings and revenue. The company reported an EPS of $0.05 against expectations of $0.03, while total revenue reached $201.66 million. This positive performance was primarily driven by a 14% increase in clinical testing revenue and a 12% rise in the average revenue generated per test.

Per market data and financial reports, the next-generation sequencing (NGS) segment showed remarkable year-over-year growth of 26%, becoming a key contributor representing approximately one-third of clinical revenue. Results were further bolstered by a 2% increase in test volumes, reflecting the success of the company's strategy to expand into solid-tumor and minimal residual disease (MRD) testing. The company maintains a healthy financial position with a current ratio of 3.60 and a debt-to-equity ratio of 0.57.

NEO stock stood at $13.40 (close July 28, 2026), with the shares trading between a low of $13.05 and a high of $13.62 during the session according to market data. Traders are monitoring the sustainability of this growth as the company expands its clinical lab services, while global markets remain focused on macroeconomic data impacting the healthcare sector, despite a lack of direct upcoming catalysts in the economic calendar.